(Total Views: 94)
Posted On: 05/03/2022 2:15:56 PM
Post# of 74551

$SRNE News Article - Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients https://marketwirenews.com/news-releases/leve...20035.html


My Twitter: WhyteStocks